These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
268 related articles for article (PubMed ID: 30319642)
1. Endogenous Galectin-1 in T Lymphocytes Regulates Anti-prostate Cancer Immunity. Corapi E; Carrizo G; Compagno D; Laderach D Front Immunol; 2018; 9():2190. PubMed ID: 30319642 [TBL] [Abstract][Full Text] [Related]
2. Improving cancer immunotherapy in prostate cancer by modulating T cell function through targeting the galectin-1. Wang HC; Xia R; Chang WH; Hsu SW; Wu CT; Chen CH; Shih TC Front Immunol; 2024; 15():1372956. PubMed ID: 38953033 [TBL] [Abstract][Full Text] [Related]
3. Galectin-3 in Prostate Cancer Stem-Like Cells Is Immunosuppressive and Drives Early Metastasis. Caputo S; Grioni M; Brambillasca CS; Monno A; Brevi A; Freschi M; Piras IS; Elia AR; Pieri V; Baccega T; Lombardo A; Galli R; Briganti A; Doglioni C; Jachetti E; Bellone M Front Immunol; 2020; 11():1820. PubMed ID: 33013832 [TBL] [Abstract][Full Text] [Related]
4. A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease. Laderach DJ; Gentilini LD; Giribaldi L; Delgado VC; Nugnes L; Croci DO; Al Nakouzi N; Sacca P; Casas G; Mazza O; Shipp MA; Vazquez E; Chauchereau A; Kutok JL; Rodig SJ; Elola MT; Compagno D; Rabinovich GA Cancer Res; 2013 Jan; 73(1):86-96. PubMed ID: 23108139 [TBL] [Abstract][Full Text] [Related]
5. Galectin-1 fosters an immunosuppressive microenvironment in colorectal cancer by reprogramming CD8 Cagnoni AJ; Giribaldi ML; Blidner AG; Cutine AM; Gatto SG; Morales RM; Salatino M; Abba MC; Croci DO; Mariño KV; Rabinovich GA Proc Natl Acad Sci U S A; 2021 May; 118(21):. PubMed ID: 34006646 [TBL] [Abstract][Full Text] [Related]
6. Immunosuppressive Roles of Galectin-1 in the Tumor Microenvironment. Huang Y; Wang HC; Zhao J; Wu MH; Shih TC Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680031 [TBL] [Abstract][Full Text] [Related]
7. Combining inhibition of galectin-3 with and before a therapeutic vaccination is critical for the prostate-tumor-free outcome. Tiraboschi C; Gentilini L; Velazquez C; Corapi E; Jaworski FM; Garcia Garcia JD; Rondón Y; Chauchereau A; Laderach DJ; Compagno D J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33293356 [TBL] [Abstract][Full Text] [Related]
8. A minigene DNA vaccine encoding peptide epitopes derived from Galectin-1 has protective antitumoral effects in a model of neuroblastoma. Liebscher L; Weißenborn C; Langwisch S; Gohlke BO; Preissner R; Rabinovich GA; Christiansen N; Christiansen H; Zenclussen AC; Fest S Cancer Lett; 2021 Jul; 509():105-114. PubMed ID: 33848518 [TBL] [Abstract][Full Text] [Related]
9. Ganoderic acid T, a Ganoderma triterpenoid, modulates the tumor microenvironment and enhances the chemotherapy and immunotherapy efficacy through downregulating galectin-1 levels. Chen S; Chen K; Lin Y; Wang S; Yu H; Chang C; Cheng T; Hsieh C; Li J; Lai H; Chen D; Huang C Toxicol Appl Pharmacol; 2024 Oct; 491():117069. PubMed ID: 39142358 [TBL] [Abstract][Full Text] [Related]
11. Trypanosoma cruzi Infection Imparts a Regulatory Program in Dendritic Cells and T Cells via Galectin-1-Dependent Mechanisms. Poncini CV; Ilarregui JM; Batalla EI; Engels S; Cerliani JP; Cucher MA; van Kooyk Y; González-Cappa SM; Rabinovich GA J Immunol; 2015 Oct; 195(7):3311-24. PubMed ID: 26324777 [TBL] [Abstract][Full Text] [Related]
12. Development of a nascent galectin-1 chimeric molecule for studying the role of leukocyte galectin-1 ligands and immune disease modulation. Cedeno-Laurent F; Barthel SR; Opperman MJ; Lee DM; Clark RA; Dimitroff CJ J Immunol; 2010 Oct; 185(8):4659-72. PubMed ID: 20844192 [TBL] [Abstract][Full Text] [Related]
13. Galectin-1 is a local but not systemic immunomodulatory factor in mesenchymal stromal cells. Fajka-Boja R; Urbán VS; Szebeni GJ; Czibula Á; Blaskó A; Kriston-Pál É; Makra I; Hornung Á; Szabó E; Uher F; Than NG; Monostori É Cytotherapy; 2016 Mar; 18(3):360-70. PubMed ID: 26857229 [TBL] [Abstract][Full Text] [Related]
14. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Rubinstein N; Alvarez M; Zwirner NW; Toscano MA; Ilarregui JM; Bravo A; Mordoh J; Fainboim L; Podhajcer OL; Rabinovich GA Cancer Cell; 2004 Mar; 5(3):241-51. PubMed ID: 15050916 [TBL] [Abstract][Full Text] [Related]
15. Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity. Sturgill ER; Rolig AS; Linch SN; Mick C; Kasiewicz MJ; Sun Z; Traber PG; Shlevin H; Redmond WL Oncoimmunology; 2021 Mar; 10(1):1892265. PubMed ID: 33717655 [TBL] [Abstract][Full Text] [Related]
16. Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy. Van Woensel M; Mathivet T; Wauthoz N; Rosière R; Garg AD; Agostinis P; Mathieu V; Kiss R; Lefranc F; Boon L; Belmans J; Van Gool SW; Gerhardt H; Amighi K; De Vleeschouwer S Sci Rep; 2017 Apr; 7(1):1217. PubMed ID: 28450700 [TBL] [Abstract][Full Text] [Related]
19. Involvement of Galectin-1 Tumor Microenvironment in Radiosensitivity. Chen YF; Wang CC; Hsu CY; Huang EY Anticancer Res; 2021 May; 41(5):2321-2331. PubMed ID: 33952457 [TBL] [Abstract][Full Text] [Related]
20. Silencing the expression of Cbl-b enhances the immune activation of T lymphocytes against RM-1 prostate cancer cells in vitro. Zhou SK; Chen WH; Shi ZD; Wang SP; Li L; Wen XF; Wang YM J Chin Med Assoc; 2014 Dec; 77(12):630-6. PubMed ID: 25249301 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]